Literature DB >> 22795726

Risk factors for extreme-drug resistant Pseudomonas aeruginosa infections in patients with hematologic malignancies.

Yin-Xin Liew1, Thuan-Tong Tan, Winnie Lee, Jern-Lin Ng, De-Qing Chia, Gee-Chuan Wong, Andrea L Kwa.   

Abstract

BACKGROUND: Extreme-drug resistant Pseudomonas aeruginosa (XDRPa) infection has emerged in our hematologic unit and is associated with increased mortality. Treatment options are limited, and infection prevention is currently the best option. We aimed to identify the risk factors for XDRPa infection in patients with hematologic malignancies to facilitate institution of stringent infection control measures.
METHODS: This was a retrospective matched case-control study (26 cases and 53 controls). XDRPa was detected using pulsed-field gel electrophoresis. Data were analyzed by conditional logistic regression and conditional multivariate logistic regression using Stata MP10.
RESULTS: Seventy-nine patients (49 males and 30 females; median age, 47 years; range, 16-79 years) were evaluated between December 2006 and December 2008. Independent predictors were use of carbapenem (odds ratio [OR], 10.63; 95% confidence interval [CI], 1.88-59.94; P < .01), Foley catheter insertion (OR, 11.24; 95% CI, 1.075-117.62; P = .04), and bone marrow aspiration (OR, 16.41; 95% CI, 1.57-171.73; P = .02). PFGE revealed 4 patterns. These XDRPa infections were borderline susceptible or resistant to polymyxin B and resistant to all other classes of antibiotics. The infection-attributed mortality of XDRPa was 53%. The median duration of hospitalization was 41 days (range, 19-83 days) in cases after XDRPa isolation and 28 days (range, 5-97 days) in controls.
CONCLUSIONS: The independent predictors for XDRPa infection were carbapenem use during the current admission, Foley catheter insertion, and bone marrow aspiration. More stringent infection control measures should be applied for patients with these predictors.
Copyright © 2013 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22795726     DOI: 10.1016/j.ajic.2012.02.025

Source DB:  PubMed          Journal:  Am J Infect Control        ISSN: 0196-6553            Impact factor:   2.918


  6 in total

1.  The prophylactic effects of human IgG derived from sera containing high anti-PcrV titers against pneumonia-causing Pseudomonas aeruginosa.

Authors:  Mao Kinoshita; Hideya Kato; Hiroaki Yasumoto; Masaru Shimizu; Saeko Hamaoka; Yoshifumi Naito; Koichi Akiyama; Kiyoshi Moriyama; Teiji Sawa
Journal:  Hum Vaccin Immunother       Date:  2016-07-25       Impact factor: 3.452

Review 2.  Emergence of antibiotic resistance Pseudomonas aeruginosa in intensive care unit; a critical review.

Authors:  Preeti Pachori; Ragini Gothalwal; Puneet Gandhi
Journal:  Genes Dis       Date:  2019-04-17

3.  Risk factors for acquisition of carbapenem-resistance during treatment with carbapenem in the intensive care unit: a prospective study.

Authors:  François Labaste; Julia Grossac; Fanny Vardon Bounes; Jean-Marie Conil; Stéphanie Ruiz; Thierry Seguin; Marion Grare; Olivier Fourcade; Vincent Minville; Bernard Georges
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-09-03       Impact factor: 3.267

4.  Clinical and treatment-related risk factors for nosocomial colonisation with extensively drug-resistant Pseudomonas aeruginosa in a haematological patient population: a matched case control study.

Authors:  Matthias Willmann; Anna M Klimek; Wichard Vogel; Jan Liese; Matthias Marschal; Ingo B Autenrieth; Silke Peter; Michael Buhl
Journal:  BMC Infect Dis       Date:  2014-12-10       Impact factor: 3.090

5.  Epidemiology and risk factors of extensively drug-resistant Pseudomonas aeruginosa infections.

Authors:  Nattawan Palavutitotai; Anupop Jitmuang; Sasima Tongsai; Pattarachai Kiratisin; Nasikarn Angkasekwinai
Journal:  PLoS One       Date:  2018-02-22       Impact factor: 3.240

6.  Risk factors for hospitalized patients with resistant or multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis.

Authors:  Gowri Raman; Esther E Avendano; Jeffrey Chan; Sanjay Merchant; Laura Puzniak
Journal:  Antimicrob Resist Infect Control       Date:  2018-07-04       Impact factor: 4.887

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.